Novartis Analyst Ratings
Novartis Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 05/09/2022 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/06/2021 | — | Exane BNP Paribas | Downgrades | Outperform → Neutral | |
| 12/03/2021 | — | Bryan Garnier | Downgrades | Buy → Neutral | |
| 09/20/2021 | — | Deutsche Bank | Downgrades | Hold → Sell | |
| 03/10/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 02/01/2021 | 3.82% | Cowen & Co. | $110 → $105 | Downgrades | Outperform → Market Perform |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 09/01/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 02/25/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/25/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 04/10/2019 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 12/11/2018 | 3.82% | Jefferies | → $105 | Assumes | → Buy |
| 11/26/2018 | -1.13% | Cowen & Co. | → $100 | Upgrades | Market Perform → Outperform |
| 11/19/2018 | — | Goldman Sachs | Upgrades | Neutral → Conviction Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/25/2023 | - | 摩根士丹利 | 升級 | 重量不足的→等重 | |
| 05/09/2022 | - | 沃爾夫研究 | 評級下調 | 超越→同行的表現 | |
| 12/06/2021 | - | 法國巴黎銀行 | 評級下調 | 跑贏→中性 | |
| 12/03/2021 | - | 布萊恩·加尼耶 | 評級下調 | 購買→中性 | |
| 09/20/2021 | - | 德意志銀行 | 評級下調 | 持有→Sell | |
| 03/10/2021 | - | Argus研究 | 評級下調 | 購買→Hold | |
| 02/01/2021 | 3.82% | 考恩公司 | $110→$105 | 評級下調 | 跑贏→市場表現 |
| 2021/01/15 | - | 德意志銀行 | 開始承保 | →購買 | |
| 09/01/2020 | - | 摩根士丹利 | 升級 | 等重→超重 | |
| 02/25/2020 | - | 古根海姆 | 評級下調 | 購買→中性 | |
| 2019年04月25日 | - | 古根海姆 | 升級 | 中性→購買 | |
| 2019年04月10日 | - | 摩根士丹利 | 評級下調 | 等重→減碼 | |
| 2018年12月11日 | 3.82% | 傑富瑞 | →$105 | 假設 | →購買 |
| 2018年11月26日 | -1.13% | 考恩公司 | →$100 | 升級 | 市場表現優於→ |
| 2018年11月19日 | - | 高盛 | 升級 | 中性→定罪買入 |
What is the target price for Novartis (NVS)?
諾華(Novartis)的目標價是多少？
The latest price target for Novartis (NYSE: NVS) was reported by Morgan Stanley on September 25, 2023. The analyst firm set a price target for $0.00 expecting NVS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
諾華公司(紐約證券交易所代碼：NVS)的最新目標價是由摩根士丹利於2023年9月25日報道的。這家分析公司將NVS的目標價設定為0.00美元，預計NVS將在12個月內下降(跌幅可能為-100.00%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Novartis (NVS)?
分析師對諾華(Novartis)的最新評級是多少？
The latest analyst rating for Novartis (NYSE: NVS) was provided by Morgan Stanley, and Novartis upgraded their equal-weight rating.
分析師對諾華公司(紐約證券交易所股票代碼：NVS)的最新評級由摩根士丹利提供，諾華公司上調了其同等權重的評級。
When is the next analyst rating going to be posted or updated for Novartis (NVS)?
諾華公司(Novartis)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novartis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novartis was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與諾華的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。諾華的上一次評級是在2023年9月25日提交的，所以你應該預計下一次評級將在2024年9月25日左右的某個時候公佈。
Is the Analyst Rating Novartis (NVS) correct?
分析師對諾華(Novartis)的評級正確嗎？
While ratings are subjective and will change, the latest Novartis (NVS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novartis (NVS) is trading at is $101.14, which is out of the analyst's predicted range.
雖然評級是主觀的，而且會發生變化，但諾華(Novartis)最新的評級被上調，目標價從0.00美元到0.00美元。諾華公司目前的股價為101.14美元，超出了分析師的預測範圍。